vs

Side-by-side financial comparison of NewtekOne, Inc. (NEWT) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

NewtekOne, Inc. is the larger business by last-quarter revenue ($73.3M vs $69.8M, roughly 1.1× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 111.8%, a 272.2% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs -2.7%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 12.2%).

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

NEWT vs RIGL — Head-to-Head

Bigger by revenue
NEWT
NEWT
1.1× larger
NEWT
$73.3M
$69.8M
RIGL
Growing faster (revenue YoY)
RIGL
RIGL
+23.9% gap
RIGL
21.2%
-2.7%
NEWT
Higher net margin
RIGL
RIGL
272.2% more per $
RIGL
384.0%
111.8%
NEWT
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
12.2%
NEWT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NEWT
NEWT
RIGL
RIGL
Revenue
$73.3M
$69.8M
Net Profit
$19.5M
$268.1M
Gross Margin
91.5%
Operating Margin
33.2%
Net Margin
111.8%
384.0%
Revenue YoY
-2.7%
21.2%
Net Profit YoY
6.6%
1769.2%
EPS (diluted)
$0.64
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEWT
NEWT
RIGL
RIGL
Q4 25
$73.3M
$69.8M
Q3 25
$74.9M
$69.5M
Q2 25
$70.2M
$101.7M
Q1 25
$66.3M
$53.3M
Q4 24
$75.4M
$57.6M
Q3 24
$62.8M
$55.3M
Q2 24
$61.1M
$36.8M
Q1 24
$58.3M
$29.5M
Net Profit
NEWT
NEWT
RIGL
RIGL
Q4 25
$19.5M
$268.1M
Q3 25
$17.9M
$27.9M
Q2 25
$13.7M
$59.6M
Q1 25
$9.4M
$11.4M
Q4 24
$18.3M
$14.3M
Q3 24
$11.9M
$12.4M
Q2 24
$10.9M
$-1.0M
Q1 24
$9.7M
$-8.2M
Gross Margin
NEWT
NEWT
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
NEWT
NEWT
RIGL
RIGL
Q4 25
33.2%
Q3 25
40.9%
Q2 25
60.1%
Q1 25
23.9%
Q4 24
28.9%
Q3 24
25.4%
Q2 24
1.2%
Q1 24
-23.6%
Net Margin
NEWT
NEWT
RIGL
RIGL
Q4 25
111.8%
384.0%
Q3 25
23.9%
40.2%
Q2 25
19.5%
58.6%
Q1 25
14.1%
21.5%
Q4 24
24.3%
24.9%
Q3 24
19.0%
22.5%
Q2 24
17.9%
-2.8%
Q1 24
16.6%
-27.9%
EPS (diluted)
NEWT
NEWT
RIGL
RIGL
Q4 25
$0.64
$14.11
Q3 25
$0.67
$1.46
Q2 25
$0.52
$3.28
Q1 25
$0.35
$0.63
Q4 24
$0.70
$0.82
Q3 24
$0.45
$0.70
Q2 24
$0.43
$-0.06
Q1 24
$0.38
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEWT
NEWT
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$155.0M
Total DebtLower is stronger
$819.9M
$52.5M
Stockholders' EquityBook value
$397.6M
$391.5M
Total Assets
$2.7B
$513.6M
Debt / EquityLower = less leverage
2.06×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEWT
NEWT
RIGL
RIGL
Q4 25
$155.0M
Q3 25
$137.1M
Q2 25
$108.4M
Q1 25
$77.1M
Q4 24
$77.3M
Q3 24
$61.1M
Q2 24
$49.1M
Q1 24
$49.5M
Total Debt
NEWT
NEWT
RIGL
RIGL
Q4 25
$819.9M
$52.5M
Q3 25
$748.5M
$60.0M
Q2 25
$657.3M
$60.0M
Q1 25
$774.0M
$60.0M
Q4 24
$708.0M
$60.0M
Q3 24
$655.8M
$60.0M
Q2 24
$652.0M
$60.0M
Q1 24
$662.5M
$60.0M
Stockholders' Equity
NEWT
NEWT
RIGL
RIGL
Q4 25
$397.6M
$391.5M
Q3 25
$386.7M
$117.6M
Q2 25
$312.2M
$81.9M
Q1 25
$302.3M
$18.6M
Q4 24
$296.3M
$3.3M
Q3 24
$281.8M
$-14.6M
Q2 24
$274.0M
$-29.9M
Q1 24
$254.1M
$-31.7M
Total Assets
NEWT
NEWT
RIGL
RIGL
Q4 25
$2.7B
$513.6M
Q3 25
$2.4B
$242.5M
Q2 25
$2.1B
$206.7M
Q1 25
$2.1B
$176.0M
Q4 24
$2.1B
$164.0M
Q3 24
$1.7B
$139.4M
Q2 24
$1.6B
$128.4M
Q1 24
$1.5B
$126.5M
Debt / Equity
NEWT
NEWT
RIGL
RIGL
Q4 25
2.06×
0.13×
Q3 25
1.94×
0.51×
Q2 25
2.11×
0.73×
Q1 25
2.56×
3.23×
Q4 24
2.39×
18.25×
Q3 24
2.33×
Q2 24
2.38×
Q1 24
2.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEWT
NEWT
RIGL
RIGL
Operating Cash FlowLast quarter
$-579.2M
$22.0M
Free Cash FlowOCF − Capex
$-579.3M
FCF MarginFCF / Revenue
-790.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
-29.64×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEWT
NEWT
RIGL
RIGL
Q4 25
$-579.2M
$22.0M
Q3 25
$-167.3M
$24.0M
Q2 25
$-199.8M
$30.5M
Q1 25
$-60.7M
$-893.0K
Q4 24
$-153.0M
$14.5M
Q3 24
$-25.7M
$21.7M
Q2 24
$2.9M
$302.0K
Q1 24
$-38.7M
$-5.0M
Free Cash Flow
NEWT
NEWT
RIGL
RIGL
Q4 25
$-579.3M
Q3 25
$-167.3M
Q2 25
$-199.9M
Q1 25
$-60.7M
Q4 24
$-153.5M
Q3 24
$-25.9M
Q2 24
$2.9M
Q1 24
$-38.7M
FCF Margin
NEWT
NEWT
RIGL
RIGL
Q4 25
-790.0%
Q3 25
-223.3%
Q2 25
-284.7%
Q1 25
-91.6%
Q4 24
-203.6%
Q3 24
-41.2%
Q2 24
4.7%
Q1 24
-66.5%
Capex Intensity
NEWT
NEWT
RIGL
RIGL
Q4 25
0.1%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.6%
Q3 24
0.4%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
NEWT
NEWT
RIGL
RIGL
Q4 25
-29.64×
0.08×
Q3 25
-9.35×
0.86×
Q2 25
-14.58×
0.51×
Q1 25
-6.48×
-0.08×
Q4 24
-8.35×
1.01×
Q3 24
-2.15×
1.75×
Q2 24
0.27×
Q1 24
-4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons